In terms of prior therapy, fewer patients from Japan had been treated with prior endocrine therapy for advanced breast cancer (65.4%) or CDK4/6 inhibitors (16.7%) compared with the global CAPItello-291 population (86.7% and 70.1%, respectively); as such, more patients in Japan received study treatment as their first-line treatment. Here, CDK4 is linked to breast cancer.